The inflammasome: a remote control for metabolic syndrome.
作者信息
Lamkanfi Mohamed, Kanneganti Thirumala-Devi
机构信息
Department of Biochemistry, Ghent University, Ghent, Belgium.
出版信息
Cell Res. 2012 Jul;22(7):1095-8. doi: 10.1038/cr.2012.55. Epub 2012 Apr 10.
Abstract
摘要
相似文献
1
The inflammasome: a remote control for metabolic syndrome.炎性小体：代谢综合征的远程控制器
Cell Res. 2012 Jul;22(7):1095-8. doi: 10.1038/cr.2012.55. Epub 2012 Apr 10.
2
Metabolic syndrome: is Nlrp3 inflammasome a trigger or a target of insulin resistance?代谢综合征：Nlrp3 炎性小体是胰岛素抵抗的触发因素还是靶点？
Circ Res. 2011 May 13;108(10):1160-2. doi: 10.1161/RES.0b013e318220b57b.
3
Metaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome.代谢炎症：代谢综合征中 NLRP3 炎症小体平台的组织特异性改变。
Curr Med Chem. 2018;25(11):1294-1310. doi: 10.2174/0929867324666170407123522.
4
Inflammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis.胃肠道中的炎性体：感染、癌症和肠道微生物组稳态。
Nat Rev Gastroenterol Hepatol. 2018 Dec;15(12):721-737. doi: 10.1038/s41575-018-0054-1.
5
Inflammasomes in health and disease.炎症小体在健康与疾病中的作用。
Nature. 2012 Jan 18;481(7381):278-86. doi: 10.1038/nature10759.
6
[Metabolic syndrome and liver: the role of leptin].[代谢综合征与肝脏：瘦素的作用]
Nihon Shokakibyo Gakkai Zasshi. 2005 Nov;102(11):1392-7.
7
The cardiometabolic syndrome and liver disease.心脏代谢综合征与肝脏疾病
J Cardiometab Syndr. 2008 Winter;3(1):5-6. doi: 10.1111/j.1559-4572.2008.08248.x.
8
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.炎症小体介导的微生态失调调控非酒精性脂肪性肝病和肥胖的进展。
Nature. 2012 Feb 1;482(7384):179-85. doi: 10.1038/nature10809.
9
SIRT3 deficiency-induced mitochondrial dysfunction and inflammasome formation in the brain.SIRT3 缺乏诱导的大脑中线粒体功能障碍和炎性体形成。
Sci Rep. 2018 Dec 3;8(1):17547. doi: 10.1038/s41598-018-35890-7.
10
Supplementation of monounsaturated and polyunsaturated fatty acids in non-alcoholic fatty liver disease and metabolic syndrome.非酒精性脂肪性肝病和代谢综合征中补充单不饱和脂肪酸和多不饱和脂肪酸
Lipids. 2011 May;46(5):389-90. doi: 10.1007/s11745-011-3544-2. Epub 2011 Mar 16.
引用本文的文献
1
NLRP3 Inflammasome Activation in Liver Disorders: From Molecular Pathways to Therapeutic Strategies.肝脏疾病中的NLRP3炎性小体激活：从分子途径到治疗策略
J Inflamm Res. 2025 Jun 24;18:8277-8294. doi: 10.2147/JIR.S532908. eCollection 2025.
2
Effects of Space Flight on Inflammasome Activation in the Brain of Mice.太空飞行对小鼠大脑中炎性小体激活的影响。
Cells. 2025 Mar 12;14(6):417. doi: 10.3390/cells14060417.
3
The Metabolic Syndrome, a Human Disease.代谢综合征，一种人类疾病。
Int J Mol Sci. 2024 Feb 13;25(4):2251. doi: 10.3390/ijms25042251.
4
Relevance and consequence of chronic inflammation for obesity development.慢性炎症对肥胖发展的相关性及影响
Mol Cell Pediatr. 2023 Nov 14;10(1):16. doi: 10.1186/s40348-023-00170-6.
5
Ginseng Saponin Enriched in Rh1 and Rg2 Ameliorates Nonalcoholic Fatty Liver Disease by Inhibiting Inflammasome Activation.富含Rh1和Rg2的人参皂苷通过抑制炎性小体激活改善非酒精性脂肪性肝病。
Nutrients. 2021 Mar 5;13(3):856. doi: 10.3390/nu13030856.
6
Echinatin effectively protects against NLRP3 inflammasome-driven diseases by targeting HSP90.穿心莲内酯通过靶向 HSP90 有效防治 NLRP3 炎性小体驱动的疾病。
JCI Insight. 2021 Jan 25;6(2):134601. doi: 10.1172/jci.insight.134601.
7
Increased Serum Angiotensin II Is a Risk Factor of Nonalcoholic Fatty Liver Disease: A Prospective Pilot Study.血清血管紧张素II升高是非酒精性脂肪性肝病的危险因素：一项前瞻性试点研究。
Gastroenterol Res Pract. 2019 Nov 13;2019:5647161. doi: 10.1155/2019/5647161. eCollection 2019.
8
Are Long-Chain Polyunsaturated Fatty Acids the Link between the Immune System and the Microbiome towards Modulating Cancer?长链多不饱和脂肪酸是免疫系统与微生物群之间调节癌症的联系吗？
Medicines (Basel). 2018 Sep 10;5(3):102. doi: 10.3390/medicines5030102.
9
NOD-like receptor(s) and host immune responses with Pseudomonas aeruginosa infection.NOD 样受体与铜绿假单胞菌感染的宿主免疫反应。
Inflamm Res. 2018 Jun;67(6):479-493. doi: 10.1007/s00011-018-1132-0. Epub 2018 Jan 20.
10
Inflammasome activation and function in liver disease.炎症小体的激活及其在肝脏疾病中的作用。
Nat Rev Gastroenterol Hepatol. 2015 Jul;12(7):387-400. doi: 10.1038/nrgastro.2015.94. Epub 2015 Jun 9.
本文引用的文献
1
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.炎症小体介导的微生态失调调控非酒精性脂肪性肝病和肥胖的进展。
Nature. 2012 Feb 1;482(7384):179-85. doi: 10.1038/nature10809.
2
Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut.先天免疫和微生物群在肝纤维化中的作用：肝脏和肠道之间的串扰。
J Physiol. 2012 Feb 1;590(3):447-58. doi: 10.1113/jphysiol.2011.219691. Epub 2011 Nov 28.
3
Deregulated inflammasome signaling in disease.失调的炎症小体信号在疾病中的作用。
Immunol Rev. 2011 Sep;243(1):163-73. doi: 10.1111/j.1600-065X.2011.01042.x.
4
Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury.Nod 样受体含 pyrin 结构域蛋白 6（NLRP6）在损伤时控制上皮细胞自我更新和结直肠肿瘤发生。
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9601-6. doi: 10.1073/pnas.1100981108. Epub 2011 May 18.
5
NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis.NLRP6 炎性体调节结肠微生物生态和结肠炎风险。
Cell. 2011 May 27;145(5):745-57. doi: 10.1016/j.cell.2011.04.022. Epub 2011 May 12.
6
A functional role for Nlrp6 in intestinal inflammation and tumorigenesis.Nlrp6 在肠道炎症和肿瘤发生中的功能作用。
J Immunol. 2011 Jun 15;186(12):7187-94. doi: 10.4049/jimmunol.1100412. Epub 2011 May 4.
7
Enterotypes of the human gut microbiome.人类肠道微生物组的肠型。
Nature. 2011 May 12;473(7346):174-80. doi: 10.1038/nature09944. Epub 2011 Apr 20.
8
Emerging inflammasome effector mechanisms.新兴的炎症小体效应机制。
Nat Rev Immunol. 2011 Mar;11(3):213-20. doi: 10.1038/nri2936.
9
NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis.NLRP3 炎性小体在肠道稳态的调节中起着关键作用。
Inflamm Bowel Dis. 2011 Jun;17(6):1359-72. doi: 10.1002/ibd.21478. Epub 2010 Sep 24.
10
The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis.NLRP3 炎性小体可防止实验性结肠炎期间上皮完整性的丧失和死亡率。
Immunity. 2010 Mar 26;32(3):379-91. doi: 10.1016/j.immuni.2010.03.003. Epub 2010 Mar 18.
Zotero 插件